Hefiya (Adalimumab)

Adalimumab is a monoclonal antibody that binds tightly to tumor necrosis factor‑alpha, a key cytokine in inflammatory pathways. By neutralising TNF‑α, it blocks the cascade that leads to immune‑mediated tissue damage, thereby decreasing inflammation and symptom severity in the targeted diseases.

The dosing regimen for Hefiya is individualized by the prescribing clinician based on the specific indication, patient weight, disease severity, and response to therapy. Healthcare professionals determine the appropriate amount, frequency, and duration of treatment according to approved guidelines.

The safety of adalimumab during pregnancy and lactation has not been definitively established. Clinicians should weigh the potential benefits against possible risks and discuss options with the patient. Women who are pregnant, planning pregnancy, or breastfeeding should consult their healthcare provider before starting or continuing therapy.

To request Hefiya, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling—and necessary import documentation.

Hefiya (adalimumab) is a fully human monoclonal antibody, whereas some alternatives are fusion proteins or chimeric antibodies. Clinical studies show comparable efficacy across the class for many indications, but differences exist in dosing frequency, immunogenicity risk, and specific safety profiles. Choice of therapy is guided by physician assessment of patient needs and drug characteristics.

Hefiya must be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 14 days, then return to refrigeration.

Hefiya is supplied as a pre‑filled syringe or autoinjector for subcutaneous injection. The patient or a trained caregiver injects the dose into the abdomen, thigh, or upper arm according to the prescriber's instructions. Proper aseptic technique and rotation of injection sites are recommended to minimise local reactions.

The most serious risks include severe infections such as tuberculosis, opportunistic fungal infections, and bacterial sepsis; the possible development of malignancies, particularly lymphoma; new or worsening heart failure; demyelinating neurological disorders; and rare autoimmune phenomena like lupus‑like syndrome. Patients should be monitored closely for signs of these conditions.

Hefiya is contraindicated in individuals with known hypersensitivity to adalimumab or any component of the formulation. It should also be avoided in patients with active, serious infections, uncontrolled heart failure, or those receiving live vaccines. Clinicians must evaluate each patient’s medical history before initiating therapy.